PUBLISHED DATE : Feb 2021 | Pages : 342
Fill out your details & get your free sample
Intravenous (IV) and Oral Iron Drugs Market Size, Share, Trends Analysis Report by
Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2021–2026
342 Pages
119 Tables
163 Charts
5 Regions
18 Countries
15 Companies
5 Market Segment
| Report Attribute | Details |
|---|---|
| MARKET SIZE (REVENUE) | 10 BILLION (2026) |
| CAGR | 11.6% (2021–2026) |
| Base Year | 2020 |
| Forecast Year | 2021–2026 |
| Market Segments | Route of Administration (Oral and Intravenous (IV)); Application (Nephrology, Obstetrics & Gynecology (OBGYN), Surgery, Gastroenterology, Oncology, and Heart Failure (HF)); Patient Group (Adult and Pediatric); Distribution (Hospital Pharmacies, Offline Retail Pharmacies, and Online Channels) |
| Geographic Analysis | North America, Europe, APAC, Latin America, and Middle East & Africa |
| Countries Covered | US, Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, Australia, India, Brazil, Mexico, Argentina, Saudi Arabia, Turkey, South Africa |
The global IV and oral iron drugs market size to cross USD 10 billion in 2026, growing at a CAGR of 11.6% during 2021–2026. The global IV and oral iron drugs market is expected to grow due to the prevalence of iron deficiency (ID). This deficiency is a highly widespread nutritional disorder, affecting around one-fourth of the global population, especially women and children. It is one of the predominant causes of anemia. Anemia accounts for around 9% of the total global disease burden. Several chronic diseases are frequently associated with iron deficiency anemia (IDA) such as chronic kidney disease (CKD), chronic heart failure, cancer, and inflammatory bowel diseases. As anemia is associated with chronic fatigue, diminished well-being, and impaired cognitive function, the treatment with oral and IV iron drugs reduces the need for blood transfusion in patients. Further, the WHO rates ID as the most common and widespread nutritional disorder globally, and its prevalence is expected to grow with the aging population and the incidence of various chronic disorders.
This research report includes a detailed segmentation by
Expected launches of branded IV iron drugs in new markets and expanded indication approvals for existing commercially available brands are the key factors influencing the IV iron drugs' growth. The increased uptake of branded IV drugs in the US and European countries is also expected to contribute significantly during the forecast period. Moreover, the rise in global medicine and healthcare expenditure and high-sensitivity, accuracy, easy, and convenient access to intravenous iron dosages is likely to drive the demand for IV iron drugs over the next few years.
Oral iron therapy is widely considered the first line of treatment for iron deficiency (ID) among adults and children, thereby largely driving the segment's overall growth. As it is difficult to maintain iron requirements during pregnancy via dietary, most global and regional health organizations prescribe oral supplements during the period. Global organizations, including WHO and UNICEF, recommend oral supplements for children and adolescents in countries, where the prevalence of ID and anemia is over 40%. Although several new IV drugs are emerging, oral route of drug administration is considered effective to increase hemoglobin levels, restore iron levels in the body, and treat ID.
The growing prevalence of chronic kidney disease (CKD) and nephrological disorders across the world is increasing the application of iron drugs at a faster rate, and the trend is likely to continue during the forecast period. Across the globe, one in five men and one in four women have CKD among people above 65 years of age. Hence, a high prevalence of renal failures, particularly in developing countries such as China and India, where the number of older adults is increasing, is expected to affect market growth. Approximately 70% of patients with CKD suffer from iron deficiencies, which can aggravate renal anemia. Therefore, iron therapy with IV & oral iron drugs is an essential treatment option for CKD patients.
Iron deficiency (ID) is one of the common causes of anemia in industrialized countries with a prevalence rate of 22% among pregnant women and 10% among non-pregnant. ID in women has treated treatment with iron replacement therapies. These therapies remain the front-line option to treatment despite their GI side effects. A diverse range of low-cost generic drugs is used to treat ID and iron deficiency anemia (IDA) in women and children. Further, neonates born with iron deficiency are prone to cognitive and behavioral abnormalities that persist after repletion, highlighting the need for heightened awareness of ID diagnosis and treatment with iron replacement therapies.
Adults constitute over 81% share of the global IV and oral iron drugs market. Adults dominate the market due to the high incidence and prevalence of ID and IDA in the elderly population across the globe. CKD is relatively common among adults, with a prevalence rate of up to 13%. With the increase in diabetes and hypertension incidence, CKD patients are likely to grow, thereby increasing the demand for iron drugs. Also, the percentage of the geriatric population is increasing at a significant rate worldwide, which is a key factor driving the growth of the segment.
The growing pediatric population with ID/IDA is majorly contributing to the growth of the market segment. ID is the most common cause of anemia and is also a common deficiency among nonanemic children, mainly among children of resource-limited countries. Iron is an essential nutrient to the child's growth and development and ID in the pediatric population can affect development and lead to anemia. According to the WHO, a high percentage of children aged between 2 and 14 years are anemic in developing countries, thereby highlighting the demand for oral and IV iron drug supplements.
Hospital pharmacies offer iron drugs with adequate discounts and rebates. Innovations in hospital pharmacy practice have led to the emergence of pharmacists working in community health services, aged care facilities, rehabilitation facilities, and general practice clinics. Such practices of hospital pharmacists are further driving the uptake of iron drugs via hospital pharmacies.
In 2020, the offline retail pharmacies segment accounted for over 41% of the global market. Offline retail pharmacies majorly include conventional retail chains and multi-line retailers. The distribution of iron drugs through physical/offline retail stores has increased, particularly in developing regions such as Latin America and Asia. The high prevalence of ID/IDA is a major factor in driving the market growth. Factors such as reputation, consumer awareness, customer satisfaction have increased loyalty among consumers, thereby influencing consumers to opt for retail stores. Retail stores have also highly qualified, dedicated experts, offer specialized services.
The North American IV and oral iron drugs market share is expected to witness promising growth during the forecast period. The high uptake of branded iron drugs is one of the major reasons for strong growth. Vendors offering branded drugs are generating significantly higher revenue from the US than other markets. Also, the increased healthcare spending in the US and Canada is further contributing to the growth of the market. The prevalence of ID is likely to increase during the forecast period as the number of people with conditions such as CKD, CHF, IBD, and uterine bleeding is increasing in the country. Moreover, according to the United States Renal Data System (USRDS), the number of people suffering from CKD in the US alone was around 30 million people in 2020. A stressful lifestyle and the rise in chronic conditions are factors for the increase in the number of people with ID in the region.
Vifor Pharma and Daiichi Sankyo Company are the leading players in the global IV and oral iron drugs market. However, AMAG Pharmaceuticals, PHARMACOSMOS, Sanofi, Allergan, Akebia Therapeutics, and Shield Therapeutics are other prominent players in the market with notable shares. Vendors are competing on a wide variety of factors such as innovations, marketing strategies, and distribution channels. Global companies have a wide geographic footprint, diversified product portfolio, and a strong focus on product innovation, R&D, and business expansion activities. Key players are expected to drive sales and margin growth in their business by expanding sales organization, maintaining technology leadership through R&D, and building clinical evidence to support the benefits of the product and services.
Route of Administration
Application
Patient Group
Distribution
Geography
Frequently Asked Questions
What is the Intravenous (IV) Iron Drugs market size and growth rate during the forecast period?
The global intravenous (IV) and oral iron drugs market is expected to cross USD 10 billion by 2026.
What is the impact of COVID-19 on the intravenous (IV) iron drugs market share?
In 2020, the revenue of the market reduced with the outbreak of the COVID-19 pandemic.
North America and Europe are projected to contribute significantly to the global IV and oral drugs market during the forecast period.
Who are the notable market players in the global intravenous (IV) iron and oral iron drugs market?
Vifor Pharma and Daiichi Sankyo Company are the leading players in the market. However, AMAG Pharmaceutical, Akebia Therapeutics, Shield Therapeutics, PHARMACOSMOS, Allergan, and Sanofi are a few notable and prominent vendors in the market.
What are the opportunities and threats faced by key vendors in the market?
A high presence of generic manufacturers is increasing the threat among key vendors in the market.
The global IV and oral iron drugs market by revenue is expected to grow at a CAGR of 11.6% during the period 2021–2026.
The following factors are likely to contribute to the growth of the IV and Oral Iron Drugs market during the forecast period:
Base Year: 2020
Forecast Year: 2021–2026
The study considers the present scenario of the IV and Iron drugs market and its market dynamics for the period 2020−2026. It covers a detailed overview of several market growth enablers, restraints, and trends. The report offers both the demand and supply aspects of the market. It profiles and examines leading companies and other prominent ones operating in the market.
Prominent Vendors
Other Prominent Vendors
Other Vendors
Route of Administration
Application
Patient Group
Distribution
Geography
1 Research Methodology
2 Research Objectives
3 Research Process
4 Scope & Coverage
4.1 Market Definition
4.1.1 Inclusions
4.1.2 Exclusions
4.2 Base Year
4.3 Scope of The Study
4.4 Market Segments
4.4.1 Market Segmentation by Route of Administration (ROA)
4.4.2 Market Segmentation by Application
4.4.3 Market Segmentation by Patient Group
4.4.4 Market Segmentation by Distribution
4.4.5 Market Segmentation by Geography
5 Report Assumptions & Caveats
5.1 Key Caveats
5.2 Currency Conversion
5.3 Market Derivation
6 Market at a Glance
7 Introduction
7.1 Iron Deficiency: An Overview
7.1.1 Background
7.1.2 Symptoms of ID
7.1.3 Different Causes of ID
7.1.4 Iron Drugs for the Treatment of ID
8 Market Opportunities & Trends
8.1 Strategic Collaborations & Licensing Opportunities
8.2 Investigational Iron Drugs
8.3 Increasing Availability Of Branded Iron Therapeutics And Expanded Indication Approvals
9 Market Growth Enablers
9.1 Rising Incidence/Prevalence Of Iron Deficiency
9.2 High Demand For Dextran-Free Iv Iron Therapeutics
9.3 Growing Demand For Iron Replacement Therapies Among Kidney Disease Patients
10 Market Restraints
10.1 Presence of Alternative Options For Treating ID AND IDA
10.1.1 Natural Food Intake
10.1.2 Combination Dietary Supplements & Nutritional Health Products
10.1.3 Ayurvedic Medicine & TCM
10.2 Adverse Events Associated With Oral & IV Iron Drugs
10.3 Availability of Low-Cost Generic Iron Drugs
11 Market Landscape
11.1 Market Overview
11.1.1 COVID-19 Impact on Global IV & Oral Iron Drugs Market
11.2 Market Size & Forecast
11.3 Five Forces Analysis
11.3.1 Threat of New Entrants
11.3.2 Bargaining Power of Suppliers
11.3.3 Bargaining Power of Buyers
11.3.4 Threat of Substitutes
11.3.5 Competitive Rivalry
12 Route of Administration
12.1 Market Snapshot & Growth Engine
12.2 Market Overview
12.3 IV Iron Drugs
12.3.1 Market Overview
12.3.2 Market Size & Forecast
12.3.3 IV Iron Drugs: Geography Segmentation
12.4 Oral Iron Drugs
12.4.1 Market Overview
12.4.2 Market Size & Forecast
12.4.3 Oral Iron Drugs: Geography Segmentation
13 Application
13.1 Market Snapshot & Growth Engine
13.2 Market Overview
13.3 Nephrology
13.3.1 Market Overview
13.3.2 Market Size & Forecast
13.3.3 Nephrology: Geography Segmentation
13.4 OBGYN
13.4.1 Market Overview
13.4.2 Market Size & Forecast
13.4.3 OBGYN: Geography Segmentation
13.5 Surgery
13.5.1 Market Overview
13.5.2 Market Size & Forecast
13.5.3 Surgery: Geography Segmentation
13.6 Gastroenterology
13.6.1 Market Overview
13.6.2 Market Size & Forecast
13.6.3 Gastroenterology: Geography Segmentation
13.7 Oncology
13.7.1 Market Overview
13.7.2 Market Size & Forecast
13.7.3 Oncology: Geography Segmentation
13.8 Heart Failure
13.8.1 Market Overview
13.8.2 Market Size & Forecast
13.8.3 Heart Failure: Geography Segmentation
14 Patient Group
14.1 Market Snapshot & Growth Engine
14.2 Market Overview
14.3 Adult
14.3.1 Market Overview
14.3.2 Market Size & Forecast
14.3.3 Adult: Geography Segmentation
14.4 Pediatric
14.4.1 Market Overview
14.4.2 Market Size & Forecast
14.4.3 Pediatric: Geography Segmentation
15 Distribution
15.1 Market Snapshot & Growth Engine
15.2 Market Overview
15.3 Hospital Pharmacies
15.3.1 Market Overview
15.3.2 Market Size & Forecast
15.3.3 Hospital Pharmacies: Geography Segmentation
15.4 Offline Retail Pharmacies
15.4.1 Market Overview
15.4.2 Market Size & Forecast
15.4.3 Offline Retail Pharmacies: Geography Segmentation
15.5 Online Channels
15.5.1 Market Overview
15.5.2 Market Size & Forecast
15.5.3 Online Channels: Geography Segmentation
16 Geography
16.1 Market Snapshot & Growth Engine
16.2 Geographic Overview
17 North America
17.1 Market Overview
17.2 Market Size & Forecast
17.3 North America: Route of Administration Segmentation
17.4 North America: Application Segmentation
17.5 North America: Patient Group Segmentation
17.6 North America: Distribution Segmentation
17.7 Key Countries
17.7.1 US: Market Size & Forecast
17.7.2 Canada: Market Size & Forecast
18 Europe
18.1 Market Overview
18.2 Market Size & Forecast
18.3 Europe: Route Of Administration Segmentation
18.4 Europe: Application Segmentation
18.5 Europe: Patient Group Segmentation
18.6 Europe: Distribution Segmentation
18.7 Key Countries
18.7.1 Germany: Market Size & Forecast
18.7.2 UK: Market Size & Forecast
18.7.3 France: Market Size & Forecast
18.7.4 Italy: Market Size & Forecast
18.7.5 Spain: Market Size & Forecast
19 APAC
19.1 Market Overview
19.2 Market Size & Forecast
19.4 APAC: Route of Administration Segmentation
19.5 APAC: Application Segmentation
19.6 APAC: Patient Group Segmentation
19.7 APAC: Distribution Segmentation
19.8 Key Countries
19.8.1 Japan: Market Size & Forecast
19.8.2 China: Market Size & Forecast
19.8.3 Australia: Market Size & Forecast
19.8.4 South Korea: Market Size & Forecast
19.8.5 India: Market Size & Forecast
20 Latin America
20.1 Market Overview
20.2 Market Size & Forecast
20.4 Latin America: Route of Administration Segmentation
20.5 Latin America: Application Segmentation
20.6 Latin America: Patient Group Segmentation
20.7 Latin America: Distribution Segmentation
20.8 Key Countries
20.8.1 Brazil: Market Size & Forecast
20.8.2 Mexico: Market Size & Forecast
20.8.3 Argentina: Market Size & Forecast
21 Middle East & Africa
21.1 Market Overview
21.2 Market Size & Forecast
21.3 Middle East & Africa: Route Of Administration Segmentation
21.4 Middle East & Africa: Application Segmentation
21.5 Middle East & Africa: Patient Group Segmentation
21.6 Middle East & Africa: Distribution Segmentation
21.7 Key Countries
21.7.1 Turkey: Market Size & Forecast
21.7.2 South Africa: Market Size & Forecast
21.7.3 Saudi Arabia: Market Size & Forecast
22 Competitive Landscape
22.1 Competition Overview
22.2 Market Share Analysis
22.2.1 Vifor Pharma
22.2.2 Daiichi Sankyo Company
22.2.3 AMAG Pharmaceuticals
22.2.4 Akebia Therapeutics
23 Key Company Profiles
23.1 Vifor Pharma
23.1.1 Business Overview
23.1.2 Product Offerings
23.1.3 Key Strategies
23.1.4 Key Strengths
23.1.5 Key Opportunities
23.2 Daiichi Sankyo Company
23.2.1 Business Overview
23.2.2 Product Offerings
23.2.3 Key Strategies
23.2.4 Key Strengths
23.2.5 Key Opportunities
24 Other Prominent Vendors
24.1 AMAG Pharmaceuticals
24.1.1 Business Overview
24.1.2 Product Offerings
24.1.3 Key Strategies
24.1.4 Key Strengths
24.1.5 Key Opportunities
24.2 Akebia Therapeutics
24.2.1 Business Overview
24.2.2 Product Offerings
24.2.3 Key Strategies
24.2.4 Key Strengths
24.2.5 Key Opportunities
24.3 Shield Therapeutics
24.3.1 Business Overview
24.3.2 Product Offerings
24.3.3 Key Strategies
24.3.4 Key Strengths
24.3.5 Key Opportunities
24.4 PHARMACOSMOS
24.4.1 Business Overview
24.4.2 Product Offerings
24.4.3 Key Strategies
24.4.4 Key Strengths
24.4.5 Key Opportunities
24.5 Allergan
24.5.1 Business Overview
24.5.2 Product Offerings
24.5.3 Key Strategies
24.5.4 Key Strengths
24.5.5 Key Opportunities
24.6 Sanofi
24.6.1 Business Overview
24.6.2 Product Offerings
24.6.3 Key Strategies
24.6.4 Key Strengths
24.6.5 Key Opportunities
24.7 AOP Orphan Pharmaceuticals
24.7.1 Business Overview
24.7.2 Product Offerings
24.7.3 Key Strategies
24.7.4 Key Strengths
24.7.5 Key Opportunities
25 Other Vendors
25.1 AZAD Pharma
25.1.1 Business Overview
25.1.2 Product Offerings
25.2 Ciron Drugs & Pharmaceuticals
25.2.1 Business Overview
25.2.2 Product Offerings
25.3 Pfizer
25.3.1 Business Overview
25.3.2 Product Offerings
25.4 Rockwell Medical
25.4.1 Business Overview
25.4.2 Product Offerings
25.5 Salveo Lifecare
25.5.1 Business Overview
25.5.2 Product Offerings
25.6 Sunny Pharmaceutical
25.6.1 Business Overview
25.6.2 Product Offerings
26 Report Summary
26.1 Key Takeaways
26.2 Strategic Recommendations
27 Quantitative Summary
27.1 Route of Administration
27.1.1 IV: Geography Segmentation
27.1.2 Oral: Geography Segmentation
27.2 APPLICATION
27.2.1 Nephrology: Geography Segmentation
27.2.2 Obgyn: Geography Segmentation
27.2.3 Surgery: Geography Segmentation
27.2.4 Gastroenterology: Geography Segmentation
27.2.5 Oncology: Geography Segmentation
27.2.6 Heart Failure: Geography Segmentation
27.3 Patient Group
27.3.1 Adult: Geography Segmentation
27.3.2 Pediatric: Geography Segmentation
27.4 Distribution
27.4.1 Hospital Pharmacies: Geography Segmentation
27.4.2 Offline Retail Pharmacies: Geography Segmentation
27.4.3 Online Channels: Geography Segmentation
27.5 Geography
27.5.1 North America: Route of Administration Segmentation
27.5.2 Europe: Route of Administration Segmentation
27.5.3 APAC: Route of Administration Segmentation
27.5.4 Latin America: Route of Administration Segmentation
27.5.5 Middle East & Africa: Route of Administration Segmentation
27.5.6 North America: Application Segmentation
27.5.7 Europe: Application Segmentation
27.5.8 APAC: Application Segmentation
27.5.9 Latin America: Application Segmentation
27.5.10 Middle East & Africa: Application Segmentation
27.5.11 North America: Patient Group Segmentation
27.5.12 Europe: Patient Group Segmentation
27.5.13 APAC: Patient Group Segmentation
27.5.14 Latin America: Patient Group Segmentation
27.5.15 Middle East & Africa: Patient Group Segmentation
27.5.16 North America: Distribution Segmentation
27.5.17 Europe: Distribution Segmentation
27.5.18 APAC: Distribution Segmentation
27.5.19 Latin America: Distribution Segmentation
27.5.20 Middle East & Africa: Distribution Segmentation
28 Appendix
28.1 Abbreviations
List Of Exhibits
Exhibit 1 Segmentation of Global IV & Oral Iron Drugs Market
Exhibit 2 Market Size Calculation Approach 2020
Exhibit 3 Major Negative Impacts of ID
Exhibit 4 Some of the Most Common Symptoms of ID
Exhibit 5 Global IV & Oral Iron Drugs Market by Geography 2020 (%)
Exhibit 6 Global IV & Oral Iron Drugs Market by Route of Administration 2020 (%)
Exhibit 7 Impact of Strategic Collaborations & Licensing Opportunities
Exhibit 8 Impact of Investigational Iron Drugs
Exhibit 9 Impact of Increasing Availability of Branded Iron Therapeutics and Expanded Indication Approvals
Exhibit 10 Impact of Rising Incidence/Prevalence of Iron Deficiency
Exhibit 11 Worldwide Prevalence of Anemia Among Children under Five Years 2010−2016 (%)
Exhibit 12 Global Prevalence of Anemia in Different Population Groups
Exhibit 13 Impact of High Demand for Dextran-free IV Iron Therapeutics
Exhibit 14 Vifor Pharma (Ferinject Revenue 2017−2019) ($ million)
Exhibit 15 Daiichi Sankyo Company (Injectafer Revenue 2017−2019) ($ million)
Exhibit 16 AMAG Pharmaceuticals’ (Feraheme Revenue 2017−2019) ($ million)
Exhibit 17 Impact of Growing Demand Iron Replacement Therapies Among Kidney Disease Patients
Exhibit 18 The Underlying Causes of CKD and the Subsequent Contribution of Absolute or Functional Iron Deficiency to Renal Anemia
Exhibit 19 Anemia Prevalence Rate Comparison Between General Population and CKD Patients
Exhibit 20 Prevalence of Anemia in Patients with NDD-CKD (%)
Exhibit 21 Impact of Presence of Alternative Options for Treating ID and IDA
Exhibit 22 Popular Alternative Options for Treating ID/IDA
Exhibit 23 Impact of Adverse Events Associated with Oral & IV Iron Drugs
Exhibit 24 Impact of Availability of Low-cost Generic Iron Drugs
Exhibit 25 Percentage Share of Prescription Iron Drugs by Region 2018
Exhibit 26 Global IV & Oral Iron Drugs Market 2020–2026 ($ million)
Exhibit 27 Global IV & Oral Iron Drugs Market by Geography
Exhibit 28 Global IV & Oral Iron Drugs Market by Route of Administration
Exhibit 29 Global IV & Oral Iron Drugs Market by Application
Exhibit 30 Global IV & Oral Iron Drugs Market by Patient Group
Exhibit 31 Global IV & Oral Iron Drugs Market by Distribution
Exhibit 32 Five Forces Analysis 2020
Exhibit 33 Incremental Growth by Route of Administration 2020 & 2026
Exhibit 34 Global IV & Oral Iron Drugs Market by Route of Administration
Exhibit 35 Global IV & Oral Iron Drugs Market by Route of Administration: Incremental Growth
Exhibit 36 Global IV & Oral Iron Drugs Market by Route of Administration: Absolute Growth
Exhibit 37 Global IV & Oral Iron Drugs Market by IV Route of Administration: Incremental & Absolute Growth
Exhibit 38 Global IV & Oral Iron Drugs Market by IV Iron Drugs 2020–2026 ($ million)
Exhibit 39 Incremental Growth by Geography 2020 & 2026
Exhibit 40 Global IV & Oral Iron Drugs Market by Oral Route of Administration: Incremental & Absolute Growth
Exhibit 41 Global IV & Oral Iron Drugs Market by Oral Drugs 2020–2026 ($ million)
Exhibit 42 Incremental Growth by Geography 2020 & 2026
Exhibit 43 Incremental Growth by Application 2020 & 2026
Exhibit 44 Global IV & Oral Iron Drugs Market by Application
Exhibit 45 Global IV & Oral Iron Drugs Market by Application: Incremental Growth
Exhibit 46 Global IV & Oral Iron Drugs Market by Application: Absolute Growth
Exhibit 47 Global IV & Oral Iron Drugs Market by Nephrology: Incremental & Absolute Growth
Exhibit 48 Global IV & Oral Iron Drugs Market by Nephrology 2020–2026 ($ million)
Exhibit 49 Incremental Growth by Geography 2020 & 2026
Exhibit 50 Global IV & Oral Iron Drugs Market by OBGYN: Incremental & Absolute Growth
Exhibit 51 Global IV & Oral Iron Drugs Market by OBGYN 2020–2026 ($ million)
Exhibit 52 Incremental Growth by Geography 2020 & 2026
Exhibit 53 Global IV & Oral Iron Drugs Market by Surgery: Incremental & Absolute Growth
Exhibit 54 Global IV & Oral Iron Drugs Market by Surgery 2020–2026 ($ million)
Exhibit 55 Incremental Growth by Geography 2020 & 2026
Exhibit 56 Global IV & Oral Iron Drugs Market by Gastroenterology: Incremental & Absolute Growth
Exhibit 57 Prevalence of Diagnosed GI Conditions in Selected Geographies 2018
Exhibit 58 Global IV & Oral Iron Drugs Market by Gastroenterology 2020–2026 ($ million)
Exhibit 59 Incremental Growth by Geography 2020 & 2026
Exhibit 60 Global Cancer Incidence 2018 (%)
Exhibit 61 Global IV & Oral Iron Drugs Market by Oncology: Incremental & Absolute Growth
Exhibit 62 Key Benefits of Iron Therapy in Cancer Patients
Exhibit 63 Global IV & Oral Iron Drugs Market by Oncology 2020–2026 ($ million)
Exhibit 64 Incremental Growth by Geography 2020 & 2026
Exhibit 65 Global IV & Oral Iron Drugs Market by Heart Failure: Incremental & Absolute Growth
Exhibit 66 Global IV & Oral Iron Drugs Market by Heart Failure 2020–2026 ($ million)
Exhibit 67 Incremental Growth by Geography 2020 & 2026
Exhibit 68 Incremental Growth by Patient Group 2020 & 2026
Exhibit 69 Global IV & Oral Iron Drugs Market by Patient Group
Exhibit 70 Global IV & Oral Iron Drugs Market by Patient Group: Incremental Growth
Exhibit 71 Global IV & Oral Iron Drugs Market by Patient Group: Absolute Growth
Exhibit 72 Global IV & Oral Iron Drugs Market by Adult: Incremental & Absolute Growth
Exhibit 73 Global IV & Oral Iron Drugs Market by Adults 2020–2026 ($ million)
Exhibit 74 Incremental Growth by Geography 2020 & 2026
Exhibit 75 Global Pediatric IV & Oral Iron Drugs Market: Incremental & Absolute Growth
Exhibit 76 Global Pediatric IV & Oral Iron Drugs Market 2020–2026 ($ million)
Exhibit 77 Incremental Growth by Geography 2020 & 2026
Exhibit 78 Incremental Growth by Distribution 2020 & 2026
Exhibit 79 Global IV & Oral Iron Drugs Market by Distribution
Exhibit 80 Global IV & Oral Iron Drugs Market by Distribution: Incremental Growth
Exhibit 81 Global IV & Oral Iron Drugs Market by Distribution: Absolute Growth
Exhibit 82 Global IV & Oral Iron Drugs Market by Hospital Pharmacies: Incremental & Absolute Growth
Exhibit 83 Key Role of Hospital Pharmacies in Patient Education
Exhibit 84 Global IV & Oral Iron Drugs Market by Hospital Pharmacies 2020–2026 ($ million)
Exhibit 85 Incremental Growth by Geography 2020 & 2026
Exhibit 86 Global IV & Oral Iron Drugs Market by Offline Retail Pharmacies: Incremental & Absolute Growth
Exhibit 87 Global IV & Oral Iron Drugs Market by Offline Retail Pharmacies 2020–2026 ($ million)
Exhibit 88 Incremental Growth by Geography 2020 & 2026
Exhibit 89 Global IV & Oral Iron Drugs Market by Online Channels: Incremental & Absolute Growth
Exhibit 90 Global IV & Oral Iron Drugs Market by Online Channels 2020–2026 ($ million)
Exhibit 91 Incremental Growth by Geography 2020 & 2026
Exhibit 92 Incremental Growth by Geography 2020 & 2026
Exhibit 93 Global IV & Oral Iron Drugs Market by Geography
Exhibit 94 Global IV & Oral Iron Drugs Market by Geography 2020: Key Countries ($ million)
Exhibit 95 Global IV & Oral Iron Drugs Market by Geography: Incremental Growth
Exhibit 96 Global IV & Oral Iron Drugs Market by Geography: Absolute Growth
Exhibit 97 North America IV & Oral Iron Drugs Market 2020: Key Countries
Exhibit 98 North America IV & Oral Iron Drugs Market: Absolute & Incremental Growth
Exhibit 99 IV & Oral Iron Drugs Market in North America 2020–2026 ($ million)
Exhibit 100 Incremental Growth by Route of Administration 2020 & 2026
Exhibit 101 Incremental Growth by Application 2020 & 2026
Exhibit 102 Incremental Growth by Patient Group 2020 & 2026
Exhibit 103 Incremental Growth by Distribution 2020 & 2026
Exhibit 104 Incremental Growth in North America 2020 & 2026
Exhibit 105 Prevalence of CKD in US 2001−2016 (%)
Exhibit 106 IV & Oral Iron Drugs Market in US 2020–2026 ($ million)
Exhibit 107 IV & Oral Iron Drugs Market in Canada 2020–2026 ($ million)
Exhibit 108 Europe IV & Oral Iron Drugs Market 2020: Key Countries
Exhibit 109 IV & Oral Iron Drugs Market in Europe: Incremental & Absolute Growth
Exhibit 110 IV & Oral Iron Drugs Market in Europe 2020–2026 ($ million)
Exhibit 111 Incremental Growth by Route of Administration 2020 & 2026
Exhibit 112 Incremental Growth by Application 2020 & 2026
Exhibit 113 Incremental Growth by Patient Group 2020 & 2026
Exhibit 114 Incremental Growth by Distribution 2020 & 2026
Exhibit 115 Incremental Growth in Europe 2020 & 2026
Exhibit 116 IV & Oral Iron Drugs Market in Germany 2020–2026 ($ million)
Exhibit 117 IV & Oral Iron Drugs Market in UK 2020–2026 ($ million)
Exhibit 118 IV & Oral Iron Drugs Market in France 2020–2026 ($ million)
Exhibit 119 IV & Oral Iron Drugs Market in Italy 2020–2026 ($ million)
Exhibit 120 IV & Oral Iron Drugs Market in Spain 2020–2026 ($ million)
Exhibit 121 APAC IV & Oral Iron Drugs Market 2020: Key Countries
Exhibit 122 APAC IV & Oral Iron Drugs Market: Incremental & Absolute Growth
Exhibit 123 IV & Oral Iron Drugs Market in APAC 2020–2026 ($ million)
Exhibit 124 Health Access & Quality Index Score for Key APAC Countries 2016
Exhibit 125 Incremental Growth by Route of Administration 2020 & 2026
Exhibit 126 Incremental Growth by Application 2020 & 2026
Exhibit 127 Incremental Growth by Patient Group 2020 & 2026
Exhibit 128 Incremental Growth by Distribution 2020 & 2026
Exhibit 129 Incremental Growth in APAC 2020 & 2026
Exhibit 130 IV & Oral Iron Drugs Market in Japan 2020–2026 ($ million)
Exhibit 131 IV & Oral Iron Drugs Market in China 2020–2026 ($ million)
Exhibit 132 IV & Oral Iron Drugs Market in Australia 2020–2026 ($ million)
Exhibit 133 IV & Oral Iron Drugs Market in South Korea 2020–2026 ($ million)
Exhibit 134 Prevalence of Anemia in Children & Adults 2005−2006 & 2015−2016 in India
Exhibit 135 IV & Oral Iron Drugs Market in India 2020–2026 ($ million)
Exhibit 136 Latin America IV & Oral Iron Drugs Market 2020: Key Countries
Exhibit 137 IV & Oral Iron Drugs Market in Latin America: Incremental & Absolute Growth
Exhibit 138 IV & Oral Iron Drugs Market in Latin America 2020–2026 ($ million)
Exhibit 139 Incremental Growth by Route of Administration 2020 & 2026
Exhibit 140 Incremental Growth by Application 2020 & 2026
Exhibit 141 Incremental Growth by Patient Group 2020 & 2026
Exhibit 142 Incremental Growth by Distribution 2020 & 2026
Exhibit 143 Incremental Growth in Latin America 2020 & 2026
Exhibit 144 IV & Oral Iron Drugs Market in Brazil 2020–2026 ($ million)
Exhibit 145 IV & Oral Iron Drugs Market in Mexico 2020–2026 ($ million)
Exhibit 146 IV & Oral Iron Drugs Market in Argentina 2020–2026 ($ million)
Exhibit 147 Middle East & Africa IV & Oral Iron Drugs Market 2020: Key Countries
Exhibit 148 Middle East & Africa IV & Oral Iron Drugs Market: Incremental & Absolute Growth
Exhibit 149 IV & Oral Iron Drugs Market in Middle East & Africa 2020–2026 ($ million)
Exhibit 150 Incremental Growth by Route of Administration 2020 & 2026
Exhibit 151 Incremental Growth by Application 2020 & 2026
Exhibit 152 Incremental Growth by Patient Group 2020 & 2026
Exhibit 153 Incremental Growth by Distribution 2020 & 2026
Exhibit 154 Incremental Growth in Middle East & Africa 2020 & 2026
Exhibit 155 IV & Oral Iron Drugs Market in Turkey 2020–2026 ($ million)
Exhibit 156 IV & Oral Iron Drugs Market in South Africa 2020–2026 ($ million)
Exhibit 157 IV & Oral Iron Drugs Market in Saudi Arabia 2020–2026 ($ million)
Exhibit 158 Vifor Pharma: R&D Expenditure 2017−2019 ($ million)
Exhibit 159 Vifor Pharma: Revenue by Geography 2019 (%)
Exhibit 160 Daiichi Sankyo Company: Revenue by Key Products 2018 & 2019 ($ billion)
Exhibit 161 AMAG Pharmaceuticals: R&D Expenditure 2017−2019 ($ million)
Exhibit 162 AMAG Pharmaceuticals: Feraheme Revenue 2017−2019 ($ million)
Exhibit 163 Akebia Therapeutics: R&D Expenditure 2017−2019 ($ million)
List Of Tables
Table 1 Key Caveats
Table 2 Currency Conversion 2013−2020
Table 3 Standard Requirement of Iron in Different Patient Groups
Table 4 Oral & IV Iron Therapy: Advantages and Disadvantages
Table 5 Key Characteristics of Oral and IV Iron Drugs
Table 6 Major Strategic Collaborations and Licensing Partnerships
Table 7 Key Investigational Iron Drugs
Table 8 Recent Approval/Launch of Popular Iron Drugs in Various Countries/Regions
Table 9 Recent Expanded Indication Approval of Popular Iron Drugs in Various Countries/Regions
Table 10 Percentage of Patients Affected with IDA in Various Diseases
Table 11 Popular Prescription Drugs Used for Treating IDA in CKD Patients
Table 12 Most Popular Food Sources with High Iron Levels
Table 13 Popular IV Iron Drugs by Prominent Players
Table 14 Most Common Oral Iron Drug Preparations
Table 15 Popular Oral Iron Drugs by Prominent Players
Table 16 Popular IV Iron Drugs Available for Treating ID in CKD Patients
Table 17 Factors Leading to the Development of ID and IDA Among Pregnant Women
Table 18 Iron Supplementation Dosage Among Children
Table 19 Iron Therapy Recommendation for Different Stages of Iron Deficiency in Surgical Patients
Table 20 Iron Therapy Recommendation for Different Stages of Iron Deficiency in Surgical Patients
Table 21 Iron-Containing Proteins Altered in Heart Failure Patients
Table 22 Current Guideline Recommendations for IV Iron in Heart Failure Patients
Table 23 Key Causes of Iron Deficiency Anemia in Adults
Table 24 Common Oral Iron Preparations
Table 25 Iron Recommendations for Pediatric Age Groups
Table 26 Prevalence of ID and IDA in Major European Countries
Table 27 Key Competitive Factors in the Global IV & Oral Iron Drugs Market
Table 28 Global IV & Oral Iron Drugs Market: Vendors Ranking 2020
Table 29 Vifor Pharma: Major Product Offerings
Table 30 Daiichi Sankyo Company: Major Product Offerings
Table 31 AMAG Pharmaceuticals: Major Product Offerings
Table 32 Akebia Therapeutics: Major Product Offerings
Table 33 Shield Therapeutics: Major Product Offerings
Table 34 PHARMACOSMOS: Major Product Offerings
Table 35 Allergan: Major Product Offerings
Table 36 Sanofi: Major Product Offerings
Table 37 AOP Orphan Pharmaceuticals: Major Product Offerings
Table 38 AZAD Pharma: Major Product Offerings
Table 39 Ciron Drugs & Pharmaceuticals: Major Product Offerings
Table 40 Pfizer: Major Product Offerings
Table 41 Rockwell Medical: Major Product Offerings
Table 42 Salveo Lifecare: Major Product Offerings
Table 43 Sunny Pharmaceutical: Major Product Offerings
Table 44 Global IV & Oral Iron Drugs Market by Route of Administration 2020−2026 ($ million)
Table 45 Global IV & Oral Iron Drugs Market by Route of Administration 2020−2026 (%)
Table 46 IV Segment of IV & Oral Iron Drugs Market by Geography 2020−2026 ($ million)
Table 47 IV Segment of IV & Oral Iron Drugs Market by Geography 2020−2026 (%)
Table 48 Oral Segment of IV & Oral Iron Drugs Market by Geography 2020−2026 ($ million)
Table 49 Oral Segment of IV & Oral Iron Drugs Market by Geography 2020−2026 (%)
Table 50 Global IV & Oral Iron Drugs Market by Application 2020−2026 ($ million)
Table 51 Global IV & Oral Iron Drugs Market by Application 2020−2026 (%)
Table 52 Nephrology IV & Oral Iron Drugs Market by Geography 2020−2026 ($ million)
Table 53 Nephrology IV & Oral Iron Drugs Market by Geography 2020−2026 (%)
Table 54 OBGYN IV & Oral Iron Drugs Market by Geography 2020−2026 ($ million)
Table 55 OBGYN IV & Oral Iron Drugs Market by Geography 2020−2026 (%)
Table 56 Surgery IV & Oral Iron Drugs Market by Geography 2020−2026 ($ million)
Table 57 Surgery IV & Oral Iron Drugs Market by Geography 2020−2026 (%)
Table 58 Gastroenterology IV & Oral Iron Drugs Market by Geography 2020−2026 ($ million)
Table 59 Gastroenterology IV & Oral Iron Drugs Market by Geography 2020−2026 (%)
Table 60 Oncology IV & Oral Iron Drugs Market by Geography 2020−2026 ($ million)
Table 61 Oncology IV & Oral Iron Drugs Market by Geography 2020−2026 (%)
Table 62 Heart Failure IV & Oral Iron Drugs Market by Geography 2020−2026 ($ million)
Table 63 Heart Failure IV & Oral Iron Drugs Market by Geography 2020−2026 (%)
Table 64 Global IV & Oral Iron Drugs Market by Patient Group 2020−2026 ($ million)
Table 65 Global IV & Oral Iron Drugs Market by Patient Group 2020−2026 (%)
Table 66 Adult IV & Oral Iron Drugs Market by Geography 2020−2026 ($ million)
Table 67 Adult IV & Oral Iron Drugs Market by Geography 2020−2026 (%)
Table 68 Pediatric IV & Oral Iron Drugs Market by Geography 2020−2026 ($ million)
Table 69 Pediatric IV & Oral Iron Drugs Market by Geography 2020−2026 (%)
Table 70 Global IV & Oral Iron Drugs Market by Distribution 2020−2026 ($ million)
Table 71 Global IV & Oral Iron Drugs Market by Distribution 2020−2026 (%)
Table 72 Hospital Pharmacies IV & Oral Iron Drugs Market by Geography 2020−2026 ($ million)
Table 73 Hospital Pharmacies IV & Oral Iron Drugs Market by Geography 2020−2026 (%)
Table 74 Offline Retail Pharmacies IV & Oral Iron Drugs Market by Geography 2020−2026 ($ million)
Table 75 Offline Retail Pharmacies IV & Oral Iron Drugs Market by Geography 2020−2026 (%)
Table 76 Online Channels IV & Oral Iron Drugs Market by Geography 2020−2026 ($ million)
Table 77 Online Channels IV & Oral Iron Drugs Market by Geography 2020−2026 (%)
Table 78 Global IV & Oral Iron Drugs Market by Geography 2020−2026 ($ million)
Table 79 Global IV & Oral Iron Drugs Market by Geography 2020−2026 (%)
Table 80 North America IV & Oral Iron Drugs Market by Route of Administration 2020−2026 ($ million)
Table 81 North America IV & Oral Iron Drugs Market by Route of Administration 2020−2026 (%)
Table 82 Europe IV & Oral Iron Drugs Market by Route of Administration 2020−2026 ($ million)
Table 83 Europe IV & Oral Iron Drugs Market by Route of Administration 2020−2026 (%)
Table 84 APAC IV & Oral Iron Drugs Market by Route of Administration 2020−2026 ($ million)
Table 85 APAC IV & Oral Iron Drugs Market by Route of Administration 2020−2026 (%)
Table 86 Latin America IV & Oral Iron Drugs Market by Route of Administration 2020−2026 ($ million)
Table 87 Latin America IV & Oral Iron Drugs Market by Route of Administration 2020−2026 (%)
Table 88 Middle East & Africa IV & Oral Iron Drugs Market by Route of Administration 2020−2026 ($ million)
Table 89 Middle East & Africa IV & Oral Iron Drugs Market by Route of Administration 2020−2026 (%)
Table 90 North America IV & Oral Iron Drugs Market by Application 2020−2026 ($ million)
Table 91 North America IV & Oral Iron Drugs Market by Application 2020−2026 (%)
Table 92 Europe IV & Oral Iron Drugs Market by Application 2020−2026 ($ million)
Table 93 Europe IV & Oral Iron Drugs Market by Application 2020−2026 (%)
Table 94 APAC IV & Oral Iron Drugs Market by Application 2020−2026 ($ million)
Table 95 APAC IV & Oral Iron Drugs Market by Application 2020−2026 (%)
Table 96 Latin America IV & Oral Iron Drugs Market by Application 2020−2026 ($ million)
Table 97 Latin America IV & Oral Iron Drugs Market by Application 2020−2026 (%)
Table 98 Middle East & Africa IV & Oral Iron Drugs Market by Application 2020−2026 ($ million)
Table 99 Middle East & Africa IV & Oral Iron Drugs Market by Application 2020−2026 (%)
Table 100 North America IV & Oral Iron Drugs Market by Patient Group 2020−2026 ($ million)
Table 101 North America IV & Oral Iron Drugs Market by Patient Group 2020−2026 (%)
Table 102 Europe IV & Oral Iron Drugs Market by Patient Group 2020−2026 ($ million)
Table 103 Europe IV & Oral Iron Drugs Market by Patient Group 2020−2026 (%)
Table 104 APAC IV & Oral Iron Drugs Market by Patient Group 2020−2026 ($ million)
Table 105 APAC IV & Oral Iron Drugs Market by Patient Group 2020−2026 (%)
Table 106 Latin America IV & Oral Iron Drugs Market by Patient Group 2020−2026 ($ million)
Table 107 Latin America IV & Oral Iron Drugs Market by Patient Group 2020−2026 (%)
Table 108 Middle East & Africa IV & Oral Iron Drugs Market by Patient Group 2020−2026 ($ million)
Table 109 Middle East & Africa IV & Oral Iron Drugs Market by Patient Group 2020−2026 (%)
Table 110 North America IV & Oral Iron Drugs Market by Distribution 2020−2026 ($ million)
Table 111 North America IV & Oral Iron Drugs Market by Distribution 2020−2026 (%)
Table 112 Europe IV & Oral Iron Drugs Market by Distribution 2020−2026 ($ million)
Table 113 Europe IV & Oral Iron Drugs Market by Distribution 2020−2026 (%)
Table 114 APAC IV & Oral Iron Drugs Market by Distribution 2020−2026 ($ million)
Table 115 APAC IV & Oral Iron Drugs Market by Distribution 2020−2026 (%)
Table 116 Latin America IV & Oral Iron Drugs Market by Distribution 2020−2026 ($ million)
Table 117 Latin America IV & Oral Iron Drugs Market by Distribution 2020−2026 (%)
Table 118 Middle East & Africa IV & Oral Iron Drugs Market by Distribution 2020−2026 ($ million)
Table 119 Middle East & Africa IV & Oral Iron Drugs Market by Distribution 2020−2026 (%)
Single User Licence
5 User Licence
Corporate Licence
Datasheet Licence
"The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow."
